Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AkditalCAS:AKT -0.35%84 5-Year Yield-on-Cost % is 0.88 as of Jul. 23, 2026, which is 87% above its 10-year median of 0.47. GuruFocus rates CAS:AKT with a GF Score™ of 84/100 and a GF Value™ of MAD2,171.09 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 277 Healthcare Providers & Services companies, Akdital ranks worse than 80.87% on this metric.
Akdital's yield on cost for the quarter that ended in Dec. 2025 was 0.88.
The historical rank and industry rank for Akdital's 5-Year Yield-on-Cost % or its related term are showing as below:
CAS:AKT'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.29 Med: 0.47 Max: 0.94
Current: 0.88
During the past 7 years, Akdital's highest Yield on Cost was 0.94. The lowest was 0.29. And the median was 0.47.
CAS:AKT's 5-Year Yield-on-Cost % is ranked worse than 80.87% of 277
companies
in the Healthcare Providers & Services industry
Industry Median: 2.9
vs CAS:AKT: 0.88
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Akdital 5-Year Yield-on-Cost % Related Terms
CAS:AKT vs HCA, THC, DVA: 5-Year Yield-on-Cost % Comparison
For the Medical Care Facilities subindustry, Akdital's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akdital 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Akdital's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Akdital's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Akdital is calculated as
Akdital (CAS:AKT) has a 5-Year Yield-on-Cost % of 0.88 as of Jul. 23, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Akdital and its competitors. This is 87% above median its historical median of 0.47. Over the past decade, Akdital's 5-Year Yield-on-Cost % has ranged from 0.29 to 0.94. According to the industry distribution chart, Akdital ranks #224 out of 277 companies in the Healthcare Providers & Services industry, placing it in the top 80.9%.
Is Akdital's 5-Year Yield-on-Cost % too high?
Akdital's current 5-Year Yield-on-Cost % of 0.88 is 87% above median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.29 to a high of 0.94. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 2.90. Akdital's value of 0.88 is 69.7% below this industry median. Based on the distribution chart, Akdital ranks #224 out of 277 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Akdital has a GF Score™ of 84/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Akdital's 5-Year Yield-on-Cost % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Akdital ranks #224 out of 277 companies for 5-Year Yield-on-Cost %. This places Akdital in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.90. Akdital's value of 0.88 is 69.7% below this benchmark. Historically, Akdital's own 5-Year Yield-on-Cost % has ranged from 0.29 to 0.94 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 2.90, Akdital has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.90, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akdital's current 5-Year Yield-on-Cost % of 0.88 is 69.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Akdital and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akdital's current 5-Year Yield-on-Cost % is 0.88, which is 87% above median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akdital stock overvalued right now?
Based on GuruFocus' analysis, Akdital (CAS:AKT) is currently considered Possible Value Trap. The stock's GF Value™ is MAD2,171.09, compared to a current price of MAD1,132.00 — trading 47.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.88, which is 87% above median its 10-year median of 0.47 and 69.7% below the Healthcare Providers & Services industry median of 2.90. Akdital's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Akdital (CAS:AKT), the current 5-Year Yield-on-Cost % is 0.88 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Akdital (CAS:AKT) Overvalued in 2026?
Based on GuruFocus' analysis, Akdital stock appears to be undervalued.
The current stock price of MAD1,132.00 is trading 47.9% below its estimated GF Value™ of MAD2,171.09.
GuruFocus considers Akdital to be Possible Value Trap.
Key valuation signals for CAS:AKT:
5-Year Yield-on-Cost %: 0.88 (87% above median its 10-year median of 0.47)
GF Value™: MAD2,171.09 vs. price of MAD1,132.00 (47.9% below fair value)
Industry Position: 69.7% below the Healthcare Providers & Services median (#224 of 277)
No single metric tells the full story. See the CAS:AKT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Akdital operates private healthcare clinics. The company offers healthcare services such as cardiac surgery, oncology, radiotherapy, intensive care, and neonatal care, providing patients with comprehensive care according to international standards.
84GF Score
Get the complete analysis for CAS:AKT
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:AKT has been successfully added to your 
